In the News
Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc.
Newsweek Investment Reports
Alzheon’s Pill For Alzheimer’s Recruits for Clinical Trials
beingpatient.com
Press Releases
Alzheon CEO Dr. Martin Tolar Awarded Eliška and Zdeněk Strmiska Award from Alzheimer’s Foundation for Significant Contribution Towards Research and Treatment of Alzheimer’s Disease, and Donated Cash Prize to INDRC Institute
Alzheimer’s Foundation Recognized Impact of Dr. Tolar’s Scientific Discoveries in Advancing Understanding of Alzheimer’s that Led to Development of Oral Disease Modifying Treatment ALZ-801/Valiltramiprosate
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer and Strengthens Commercial Organization with New Executive Appointments to Lead Planned U.S. Commercial Launch of Oral ALZ-801/Valiltramiprosate in 2025
ALZ-801 Has Potential to Become the First Oral Agent to Slow and Prevent Alzheimer’s Pathology in Patients and Healthy Individuals at Risk for the Disease
Alzheon CEO Dr. Martin Tolar to Discuss Positive Results from Phase 2 Biomarker Study and Upcoming Readout from Pivotal APOLLOE4 Phase 3 Study Evaluating Oral ALZ-801/Valiltramiprosate at Truist Securities BioPharma Symposium
ALZ-801 Tablet Inhibits Formation of Soluble Toxic Amyloid Aggregates and Acts Upstream from Anti-Amyloid Antibodies
Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer’s Disease Conference
Fully Enrolled Pivotal APOLLOE4 Phase 3 Trial Progressing Successfully, Enabling Topline Data Readout and NDA Filing in 2024
Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer’s Disease Day, and BIO Investor Forum
Fully Enrolled Pivotal APOLLOE4 Phase 3 Trial Progressing Successfully, Enabling Topline Data Readout and NDA Filing in 2024
Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
Early, Sustained and Statistically Significant Reduction in Plasma P-tau181 Reaching 31% at 24 Months Supports Disease Modification in Carriers of One or Two Copies of APOE4 Gene who Represent Two Thirds of Alzheimer’s Patients